High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting

Autor: Katharina Lisenko, Mathias Witzens-Harig, Hartmut Goldschmidt, Patrick Wuchter, Johann W. Schmier, Thomas Bruckner, Jens Hillengass, Gerlinde Egerer, Anthony D. Ho, Sandra Sauer, Sofia Shah
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Melphalan
Adult
Male
medicine.medical_specialty
Cancer Research
medicine.medical_treatment
Hematopoietic stem cell transplantation
Transplantation
Autologous
Outpatient supportive care
03 medical and health sciences
Young Adult
0302 clinical medicine
Autologous stem-cell transplantation
610 Medical sciences Medicine
Multiple myeloma
Internal medicine
Germany
medicine
Genetics
High-dose chemotherapy
Humans
Adverse effect
Antineoplastic Agents
Alkylating
Outpatient setting
Aged
Neoplasm Staging
Retrospective Studies
Chemotherapy
business.industry
Hematopoietic Stem Cell Transplantation
Autologous blood stem cell transplantation
Retrospective cohort study
Middle Aged
medicine.disease
Combined Modality Therapy
Surgery
Transplantation
Treatment Outcome
Oncology
030220 oncology & carcinogenesis
Female
business
030215 immunology
medicine.drug
Research Article
Zdroj: BMC Cancer
Popis: Background: High-dose (HD) chemotherapy with melphalan and autologous blood stem cell transplantation (ABSCT) for treatment of symptomatic multiple myeloma (MM) on an outpatient basis has been well established in the USA and Canada, whereas in Germany and Western Europe an inpatient setting is the current standard. We report on a German single-centre program to offer the procedure on an outpatient basis to selected patients. Methods: Major requirements included: patients had to have family and/or other caregivers, had to be able to reach the hospital within 45 min and have an ECOG performance score of 0–1. Patients with severe co-morbidities were not included. Results: From September 2012 until April 2016, 21 patients with MM stage IIIA were enrolled. All engrafted within the expected time range (median 14 days), and no severe adverse events occurred. 14 patients (67%) had an episode of neutropenic fever and blood cultures were positive in 4 patients (19%). Although rather liberal criteria for hospital admission were applied, 14 patients (67%) were treated entirely on an outpatient basis. Conclusions: HD chemotherapy and ABSCT on an outpatient basis is safe and feasible if it is conducted in an elaborate surveillance program. The feedback from patients was very positive, thus encouraging further expansion of the program.
Databáze: OpenAIRE
Externí odkaz: